First Time Loading...

Zhejiang Jolly Pharmaceutical Co Ltd
SZSE:300181

Watchlist Manager
Zhejiang Jolly Pharmaceutical Co Ltd Logo
Zhejiang Jolly Pharmaceutical Co Ltd
SZSE:300181
Watchlist
Price: 15.99 CNY -4.88%
Updated: May 16, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Zhejiang Jolly Pharmaceutical Co Ltd

Wall Street analysts forecast Zhejiang Jolly Pharmaceutical Co Ltd stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Zhejiang Jolly Pharmaceutical Co Ltd is 15.12 CNY .

Lowest Forecast
Wall Street Target
Not Available
Average Forecast
Wall Street Target
15.12 CNY
5% Downside
Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
15.12 CNY
5% Downside
Highest
Price Target
Not Available
Zhejiang Jolly Pharmaceutical Co Ltd Competitors:
Price Targets
SUPRIYA
Supriya Lifescience Ltd
12% Upside
XERS
Xeris Biopharma Holdings Inc
145% Upside
K
KDEV
Karolinska Development AB
173% Upside
000423
Dong-E-E-Jiao Co Ltd
2% Upside
SUPRIYA
Supriya Lifescience Ltd
12% Upside
XERS
Xeris Biopharma Holdings Inc
145% Upside
K
KDEV
Karolinska Development AB
173% Upside
000423
Dong-E-E-Jiao Co Ltd
2% Upside
600332
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
1% Downside
Y
3705
YungShin Global Holding Corp
1% Upside
H
3692
Hansoh Pharmaceutical Group Company Ltd
4% Upside
RX
Biosyent Inc
11% Upside

Revenue
Forecast

Revenue Estimate
Zhejiang Jolly Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Zhejiang Jolly Pharmaceutical Co Ltd's revenue is 14%. The projected CAGR for the next 2 years is 25%.

14%
Past Growth
25%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Zhejiang Jolly Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Zhejiang Jolly Pharmaceutical Co Ltd's operating income is 22%. The projected CAGR for the next 2 years is 27%.

22%
Past Growth
27%
Estimated Growth
Estimates Accuracy
17%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Zhejiang Jolly Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Zhejiang Jolly Pharmaceutical Co Ltd's net income is 21%. The projected CAGR for the next 2 years is 26%.

21%
Past Growth
26%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Zhejiang Jolly Pharmaceutical Co Ltd's stock price target?
Price Target
15.12 CNY

According to Wall Street analysts, the average 1-year price target for Zhejiang Jolly Pharmaceutical Co Ltd is 15.12 CNY .

What is Zhejiang Jolly Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
25%

For the last 8 years the compound annual growth rate for Zhejiang Jolly Pharmaceutical Co Ltd's revenue is 14%. The projected CAGR for the next 2 years is 25%.

What is Zhejiang Jolly Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
27%

For the last 8 years the compound annual growth rate for Zhejiang Jolly Pharmaceutical Co Ltd's operating income is 22%. The projected CAGR for the next 2 years is 27%.

What is Zhejiang Jolly Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
26%

For the last 8 years the compound annual growth rate for Zhejiang Jolly Pharmaceutical Co Ltd's net income is 21%. The projected CAGR for the next 2 years is 26%.

ALPHA SPREAD
Join more than 137,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.